Beyond Air, Inc. (NASDAQ:XAIR - Get Free Report) traded up 3.2% during trading on Thursday . The company traded as high as $1.74 and last traded at $1.63. 179,722 shares were traded during trading, a decline of 43% from the average session volume of 314,859 shares. The stock had previously closed at $1.58.
Beyond Air Stock Up 3.2 %
The firm has a market cap of $58.75 million, a price-to-earnings ratio of -0.77 and a beta of -0.18. The business's 50 day moving average price is $1.75 and its 200 day moving average price is $1.88. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.26 and a current ratio of 3.39.
Beyond Air (NASDAQ:XAIR - Get Free Report) last released its quarterly earnings results on Monday, February 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.61) by $0.11. The company had revenue of $0.39 million during the quarter, compared to analyst estimates of $0.49 million. During the same period in the prior year, the business posted ($0.43) EPS. On average, equities analysts forecast that Beyond Air, Inc. will post -1.93 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XAIR. Wexford Capital LP purchased a new position in Beyond Air in the 4th quarter valued at $26,000. UBS Group AG purchased a new position in shares of Beyond Air during the 1st quarter worth $30,000. Keel Point LLC purchased a new position in shares of Beyond Air during the 4th quarter worth $30,000. Scotia Capital Inc. purchased a new position in shares of Beyond Air during the 3rd quarter worth $31,000. Finally, California State Teachers Retirement System purchased a new position in shares of Beyond Air during the 2nd quarter worth $36,000. Hedge funds and other institutional investors own 31.50% of the company's stock.
About Beyond Air
(
Get Free Report)
Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Beyond Air, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beyond Air wasn't on the list.
While Beyond Air currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
